一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Telisotuzumab Vedotin，当前状态为招募中。登记地点显示中国北京、福州、南宁、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Telisotuzumab Vedotin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Chest Tumor Hospital /ID# 271935 · 北京
- Fujian Province Cancer Hospital /ID# 276178 · 福州
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931 · 南宁
- Harbin Medical University Cancer Hospital /ID# 271665 · 哈尔滨
- Henan Cancer Hospital /ID# 271927 · 郑州
- Union Hospital - Tongji Medical College /ID# 271668 · 武汉
- The First Affiliated Hospital of Nanchang University /ID# 271666 · 南昌
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928 · 西安
- LinYi Cancer Hospital /ID# 272068 · 临沂
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933 · 乌鲁木齐
公开的入选条件
- * Projected life expectancy of at least 12 weeks.
- * Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as \>= 25% tumor cells with 3+ staining (high \[\>= 50% 3+\]; intermediate \[\>= 25%
- \< 50%\]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- * Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- * Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- * Actionable alterations in genes other than EGFR are permitted.
- * Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- * Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06568939；登记信息更新于 2026-09-15。